FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014024350408/28/14 new patent  Antibodies comprising chimeric constant domains
22014024546608/28/14 new patent  Humanized t cell co-receptor mice
32014024546708/28/14 new patent  Genetically modified major histocompatibility complex mice
42014024546808/28/14 new patent  Non-human animals with modified immunoglobulin heavy chain sequences
52014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
62014021377307/31/14Adam6 mice
72014019655007/17/14Systems and devices for sample handling
82014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
92014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
102014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
112014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
122014017887906/26/14Compositions and methods for modifying cells
132014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
142014015470106/05/14Humanized fc gamma r mice
152014015568906/05/14Methods of modifying genes in eukaryotic cells
162014015744506/05/14Low affinity fcgr deficient mice
172014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
182014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
192014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
202014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
212014013471905/15/14Recombinant cell surface capture proteins
222014013727505/15/14Hybrid light chain mice
232014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
242014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
252014013471905/15/14Recombinant cell surface capture proteins
262014013727505/15/14Hybrid light chain mice
272014013019305/08/14Mice that make vl binding proteins
282014013019405/08/14Mice that make vl binding proteins
292014013019305/08/14Mice that make vl binding proteins
302014013019405/08/14Mice that make vl binding proteins
312014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
322014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
332014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
342014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
352014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
362014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
372014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
382014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
392014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
402014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
412014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
422014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
432014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
442014007297903/13/14Isolating cells expressing secreted proteins
452014007298003/13/14Isolating cells expressing secreted proteins
462014007301003/13/14Methods of modifying eukaryotic cells
472014007558603/13/14Parental cell lines for making cassette-free f1 progeny
482014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
492014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
502014007297903/13/14Isolating cells expressing secreted proteins
512014007298003/13/14Isolating cells expressing secreted proteins
522014007301003/13/14Methods of modifying eukaryotic cells
532014007558603/13/14Parental cell lines for making cassette-free f1 progeny
542014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
552014005690702/27/14Anti-asic1 antibodies and uses thereof
562014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
572014004106802/06/14Methods of modifying eukaryotic cells
582014003333601/30/14Methods of modifying eukaryotic cells
592014003333701/30/14Methods of modifying eukaryotic cells
602014002363701/23/14Methods of modifying eukaryotic cells
612014001722801/16/14Humanized light chain mice
622014001722901/16/14Methods of modifying eukaryotic cells
632014001723801/16/14Methods of modifying eukaryotic cells
642014001769501/16/14Isolating cells expressing secreted proteins
652014001778101/16/14Methods of modifying eukaryotic cells
662014001778201/16/14Methods for modifying eukaryotic cells
672014001852201/16/14Methods of modifying eukaryotic cells
682014002012401/16/14Methods of modifying eukaryotic cells
692014002012501/16/14Methods of modifying eukaryotic cells
702014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
712014001345701/09/14Methods of modifying eukaryotic cells
722013034453812/26/13Human antibodies to the glucagon receptor
732013034010412/19/13Humanized il-7 rodents
742013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
752013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
762013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
772013032326112/05/13Purified antibody composition
782013032378812/05/13Production cell line enhancers
792013032379012/05/13Human lambda light chain mice
802013032379112/05/13Restricted immunoglobulin heavy chain mice
812013032664712/05/13Human lambda light chain mice
822013030967011/21/13Nuclease-mediated targeting with large targeting vectors
832013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
842013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
852013029509711/07/13Human antibodies to fel d1 and methods of use thereof
862013028075810/24/13Fusion polypeptides capable of activating receptors
872013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
882013026657410/10/13Human antibodies to human angiopoietin-like protein 4
892013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
902013025988110/03/13Fusion polypeptides capable of activating receptors
912013026105610/03/13Vegf antagonist formulations
922013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
932013025491109/26/13Adam6 mice
942013024377509/19/13Multispecific antigen-binding molecules and uses thereof
952013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
962013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
972013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
982013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
992013023053109/05/13Human antibodies to clostridium difficile toxins
1002013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1012013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1022013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1032013020949208/15/13Anti-tie2 antibodies and uses thereof
1042013021013708/15/13Methods of modifying eukaryotic cells
1052013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1062013020949208/15/13Anti-tie2 antibodies and uses thereof
1072013021013708/15/13Methods of modifying eukaryotic cells
1082013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1092013019587808/01/13Anti-asic1 antibodies and uses thereof
1102013019887908/01/13Humanized universal light chain mice
1112013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1122013019587808/01/13Anti-asic1 antibodies and uses thereof
1132013019887908/01/13Humanized universal light chain mice
1142013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1152013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1162013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1172013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1182013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1192013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1202013018581907/18/13Genetically modified major histocompatibility complex animals
1212013018582007/18/13Genetically modified major histocompatibility complex animals
1222013018582107/18/13Common light chain mouse
1232013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1242013018581907/18/13Genetically modified major histocompatibility complex animals
1252013018582007/18/13Genetically modified major histocompatibility complex animals
1262013018582107/18/13Common light chain mouse
1272013017114907/04/13Anti-angptl3 antibodies and uses thereof
1282013017114907/04/13Anti-angptl3 antibodies and uses thereof
1292013016478606/27/13Fucosylation-deficient cells
1302013016478606/27/13Fucosylation-deficient cells
1312013015731306/20/13High affinity antibodies to human il-6 receptor
1322013016015306/20/13Humanized light chain mice
1332013015731306/20/13High affinity antibodies to human il-6 receptor
1342013016015306/20/13Humanized light chain mice
1352013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1362013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1372013013710105/30/13Methods of modifying eukaryotic cells
1382013013710105/30/13Methods of modifying eukaryotic cells
1392013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1402013012983005/23/13Polymer protein microparticles
1412013013037205/23/13Enhanced expression and stability regions
1422013013038805/23/13Methods of modifying eurakyotic cells
1432013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1442013012983005/23/13Polymer protein microparticles
1452013013037205/23/13Enhanced expression and stability regions
1462013013038805/23/13Methods of modifying eurakyotic cells
1472013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1482013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1492013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1502013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1512013011787305/09/13Humanized il-6 and il-6 receptor
1522013011787305/09/13Humanized il-6 and il-6 receptor
1532013010905305/02/13Genetically modified t cell receptor mice
1542013011161605/02/13Genetically modified major histocompatibility complex mice
1552013011161705/02/13Genetically modified major histocompatibility complex mice
1562013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1572013009628704/18/13Restricted immunoglobulin heavy chain mice
1582013008429704/04/13Anti-erbb3 antibodies and uses thereof
1592013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1602013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1612013007867503/28/13High affinity human antibodies to human il-4 receptor
1622013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1632013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1642013003490202/07/13Fusion polypeptides capable of activating receptors
1652013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1662012032210812/20/12Adam6 mice
1672012032349712/20/12Non-hypergeometric overlap probability
1682012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1692012026035710/11/12Low affinity fcgr deficient mice
1702012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1712012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1722012019230007/26/12Common light chain mouse
1732012017868307/12/12Vegf antagonist formulations
1742012016468806/28/12High affinity human antibodies to human nerve growth factor
1752012013501005/31/12High affinity human antibodies to human il-4 receptor
1762012012867905/24/12Human antibodies to the glucagon receptor
1772012011464505/10/12Use of il-1 antagonists to treat pseudogout
1782012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1792012011466505/10/12Human antibodies to human rankl
1802012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1812012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1822012010103504/26/12Vegf antagonist formulations
1832012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1842012009657204/19/12Mice that make vl binding proteins
1852012008792904/12/12Vegf antagonist formulations for intravitreal administration
1862012008300004/05/12Neuropeptide release assay for sodium channels
1872012007679003/29/12Anti-cd48 antibodies and uses thereof
1882012007086103/22/12Human lambda light chain mice
1892012007300403/22/12Hybrid light chain mice
1902012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1912012005207203/01/12High affinity human antibodies to human il-4 receptor
1922012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1932012002140901/26/12Common light chain mouse
1942012001496801/19/12Stabilized formulations containing anti-ngf antibodies
1952012000369701/05/12High affinity antibodies to human il-6 receptor
1962011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
1972011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
1982011030796612/15/11Mice expressing human voltage-gated sodium channels
1992011030796812/15/11Production of fertile xy animals from xy es cells
2002011029363012/01/11Antibodies to human gdf8
2012011028337611/17/11Methods of modifying eukaryotic cells
2022011026918711/03/11High affinity human antibodies to human il-18 receptor
2032011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2042011025655610/20/11Humanized fcgr mice
2052011025658710/20/11High affinity human antibodies to human nerve growth factor
2062011025760110/20/11Vegf antagonist formulations for intravitreal administration
2072011025871010/20/11Methods of modifying eukaryotic cells
2082011019545408/11/11Common light chain mouse
2092011018917608/04/11Methods of treating diseases with dll4 antagonists
2102011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2112011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2122011016565007/07/11Fusion polypeptides capable of activating receptors
2132011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2142011015090506/23/11Human antibodies to human delta like ligand 4
2152011015451206/23/11Humanized fc gamma r mice
2162011014593706/16/11Mice that make heavy chain antibodies
2172011010479905/05/11Multifunctional alleles
2182011008168104/07/11Human antibodies to human cd20 and method of using thereof
2192011006590203/17/11High affinity human antibodies to pcsk9
2202011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2212011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2222011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2232011002728602/03/11High affinity human antibodies to human angiopoietin-2
2242011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2252011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2262011000837401/13/11Use of il-1 antagonists to treat gout
2272010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2282010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2292010031662712/16/10Human antibodies to human il-6 receptor
2302010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2312010030443612/02/10Fucosylation-deficient cells
2322010029110711/18/10High affinity human antibodies to human il-4 receptor
2332010029162611/18/10Enhanced expression and stability regions
2342010027993311/04/10Vegf antagonist formulations
2352010023380309/16/10Fusion polypeptides capable of activating receptors
2362010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2372010016676807/01/10High affinity human antibodies to pcsk9
2382010012981705/27/10Identifying germline competent embryonic stem cells
2392010011192105/06/10Use of il-1 antagonists to treat gout
2402010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2412010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2422010004725402/25/10High affinity human antibodies to human il-4 receptor
2432010004233002/18/10Non-hypergeometric overlap probability
2442010003483302/11/10High affinity human antibodies to human il-18 receptor
2452010002147601/28/10High affinity human antibodies to human il-4 receptor
2462009028584111/19/09Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2472009027188410/29/09Es cell-derived mice from diploid host embryo injection
2482009024619910/01/09Therapeutic methods for inhibiting tumor growth with dll4 antagonists
2492009017586407/09/09Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo